Evaluation of diagnostic value to Pro BNP and Uric Acid for P.HTN in patient with sclerederma

Document Type : Original Article

Author

Abstract

According to the importance of early detection of pulmonary arterial hypertension (PAH) in scleroderma patients and identification of noninvasive and available methods, the present study aimed to investigate the relationship between serum uric acid and pro-BNP levels with PAH in scleroderma patients.
Method: This case-control study was performed on 112 patients with scleroderma referred to rheumatology department of Ahvaz Golestan Hospital in 2018. Patients were divided and enrolled to the study into two groups including with pulmonary hypertension (pulmonary artery systolic pressure greater than 40 mmHg) (n=38) and without pulmonary hypertension (no PAH symptoms) (n=74). To evaluate serum levels of pro-BNP and uric acid, 5 cc venous blood samples were taken from all patients.
Results: Mean serum uric acid level was significantly higher in the PH group (P <0.05). Although the serum level of BNP pro was higher in the PH group, there was no statistically significant difference between two groups (P >0.05). The cut-off point of uric acid and BNP pro were 6 (mg/dl) and 80 (pg/ml), respectively. The sensitivity, specificity, positive predictive value and negative predictive value of uric acid for detection of P.HTN in scleroderma patients were 65.79%, 85.13%, 71.59% and 45.83%, respectively. The sensitivity, specificity, positive predictive value and negative predictive value of Pro BNP for detection of P.HTN in scleroderma patients were 73.68%, 74.32%, 59.57% and 84.62%, respectively.
Conclusion: The results of this study demonstrated the applicability of Pro BNP and uric acid in screening and diagnosis of pulmonary hypertension in patients with scleroderma.

Keywords

References

1-Dimitroulas T, Giannakoulas G, Dimitroula H, Sfetsios T, Parcharidou D, Karvounis H, Settas L. Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: a pilot study. Rheumatol Int. 2011 Feb;31(2):263-7. doi:10.1007/s00296-010-1557-4. Epub 2010 Jul 25.
2-McMahan Z, Schoenhoff F, Eyk JEV, Wigley FM, Hummers L. Biomarkers of pulmonary hypertension in patients with scleroderma: a case–control study. Arthritis Research & Therapy. 2015; 17:201.
3-Hickey PM, Lawrie A, Condliffe R. Circulating Protein Biomarkers in Systemic Sclerosis Related Pulmonary Arterial Hypertension: A Review of Published Data. Frontiers in Medicine. 2018; 5:175. doi:10.3389/fmed.2018.00175.
4-Lefèvre G, Dauchet L, Hachulla E, Montani D, Sobanski V, Lambert M, et al. Survival and prognostic factors in systemic sclerosis–associated pulmonary hypertension: a systematic review and meta–analysis. Arthritis Rheum. 2013; 65:2412–23.doi: 10.1002/art.38029.
5-Boyilla N, Madas S. Elevated uric acid levels: a predictor of pulmonary hypertension. Int J Adv Med. 2016 Aug;3(3):484-487.
6-McLaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Associati. Circulation. 2009; 119: 2250–94.
7-Mirfeizi SZ, Lari SM, Sahebari M, Attaran D, Pourzand H, Rafatpanah H, Akhlaghi S, Mosavat D. The Relationship between Serum Pro-Brain Natriuretic Peptide (Pro-BNP) Levels and Pulmonary Arterial Hypertension (PAH) in Patients with Limited Scleroderma. J Cardiothorac Med. 2014; 2(3): 181-186.
8-Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007; 66:940-4.
9-Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trial and Research (EUSTAR) database. Ann Rheum Dis. 2010; 69:1809-15.
10-Proudman SM, Stevens WM, Sahhar J, Celermajer D. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J. 2007; 37:485-94.
11-Cavagna L, Caporall R, Klersy C, Ghio S, Albertini R, Scelsi L. Comparison of Brain Natriuretic Peptide (BNP) and NT-proBNP in Screening for Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis. J Rheumatol. 2010; 37:10; doi: 10.3899/jrheum.090997.
12-Launay D, Sitbon O, Le Pavec J, Savale L, Tchérakian C, Yaïci A, et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology. 2010; 49:490-500.
13-Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010; 138:1383-94.
14-Hachulla E, Carpentier P, Gressin V, Diot E, Allanore Y, Sibilia J, et al. ItinérAIR-Sclérodermie Study Investigators. Risk factors for death and the 3-year survival of patients with systemic sclerosis: The French ItinérAIR-Sclérodermie study. Rheumatology. 2009;48;304-8.
15-Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP, et al. Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group. J Rheumatol. 2010; 37:105-15.
16-Williams MH, Handler CE, Akram R, Smith CJ, Das C, Smee J, et al. Role of N-terminal brain natriuretic peptide (NT proBNP) in sclerodermaassociated pulmonary arterial hypertension. Eur Heart J. 2006; 27:1485-94. doi: 10.1093/eurheartj/ehi891.
17-Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum.2008;58:284-91.
18-Mathai SC, Bueso M, Hummers LK, Boyce D, Lechtzin N, Pavec JL, et al. Disproportionate Elevation of NT-proBNP in SclerodermaRelated Pulmonary Hypertensio. ERJ Express. Published on July 30, 2009. doi: 10.1183/09031936.00074309.
19-Amariei DE, Juraschek SP, Kolb TM, Damico RL, Hassoun PM, Mathai SC. The Utility of Serum Uric Acid in Predicting Pulmonary Arterial Hypertension in Patients with Scleroderma. American Journal of Respiratory and Critical Care Medicine. 2015;191: A4829.
20-Simpson C, Amariei DE, Khair R, Kolb TM, Hassoun PM, Damico RL, Mathai SC. Serum Uric Acid as a Biomarker of Disease Severity in Scleroderma Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 2018;197: A2111.
21-Kim KJ, Baek IW, Park YJ, Yoon CH, Kim WU, Cho CS. High levels of uric acid in systemic lupus erythematosus is associated with pulmonary hypertension. Int J Rheum Dis. 2015 Jun;18(5):524-32. doi: 10.1111/1756-185X.12262.
22-Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73:1340–9.
Jundishapur Scientific Medical Journal
Volume 18, Issue 4 - Serial Number 121
November and December 2019
Pages 339-346

Files

History

  • Receive Date: 05 October 2019
  • Accept Date: 05 November 2019

Share

How to cite

Statistics